Graves’ disease is one of the most common autoimmune thyroid diseases. Thyroid has the highest concentration of Selenium (Se) in the body. Se has a crucial role in the function of some thyroid enzymes; however, there are controversial results regarding administration of Se in Graves’ patients.
MethodsIn this study, Graves’ patients with orbitopathy (GO) or without orbitopathy (GD) were recruited. Healthy individuals without previous history of any diseases were enrolled as the control group. Se serum level and thyroid hormones, including T3, T4 and TSH, were measured using atomic absorption and radioimmunoassay techniques, respectively.
ResultsIn this cross-sectional study, 60 GO, 56 GD, and 58 healthy subjects with the mean age of 41.48±13.89, 41.53±12.68, and 31.25±5.61 years were enrolled, respectively. Se serum levels in the GO, GD, and control groups were 94.53±25.36, 96.82±30.3, and 102.55±16.53 μg/dl, respectively (P value: 0.193). There was a reverse association between the Se serum level and thyroid hormones, including T3, T4, and TSH, in the Go patients (P value: 0.001 rs: -0.401; P value: 0.013, rs: - 0.318; and P value<0.001, rs: 0.496). However, Se serum level had a significant reverse association with T4 and TSH hormones, but not T3 in GD patients (P value: 0.003, rs: -0.395; P value: 0.049, rs: - 0.264; and P value: 0.341, rs: - 0.129).
ConclusionOur results showed no significant difference in the Se serum level in the GO and GD patients compared with the healthy individuals. Also, we did not detect any significant difference in the Se serum level between the GO and GD patients.
留言 (0)